The therapeutic effects of recombinant adenovirus RA538 on human gastric carcinoma cells in vitro and in vivo

Table 1 Anti-proliferative effect of Ad-RA538 on SGC7901 cells (8 d, ¯x ± s)

MOI	Ad-RA538		Ad-LacZ		Mock
	A	Survival (%)	A	Survival (%)	A	Survival (%)
25	1.062±0.05	95.0±4.5	1.120±0.077	100±6.9	1.31±0.065	100±6.3
50	0.941±0.067	84.0±6.0	0.984±0.024	87.5±2.1	1.29±0.034	100±5.2
100	0.534±0.091	47.4±8.1 a	1.195±0.095	100±8.5	1.28±0.041	99.8±7.0
200	0.265±0.090	23.7±8.0 b	1.241±0.091	100±8.0	1.23±0.057	98.0±4.5

^aP < 0.05 vs Ad-LacZ or Mock;

^bP < 0.01 vs Ad-LacZ or Mock.

Table 2 Flow cytometry analysis of cell cycle effects of Ad-RA538 on SGC7901 (%)

Type of adenovirus	12 h			1 d			2 d			4 d			6 d
	G1	G2M	S	G1	G2M	S	G1	G2M	S	G1	G2M	S	G1	G2M	S
Ad-RA538	74.6	13.0	12.4	55.7	28.2	17.2	69.9	14.0a	16.1	39.7	26.6b	33.8	44.4	20.9c	34.7
Ad-LacZ	66.5	15.3	18.2	59.2	18.1	22.7	59.5	22.8	17.3	71.0	12.4	16.6	73.3	8.4	18.3

^aP < 0.01 vs Ad-LacZ; ^bP < 0.01 vs Ad-LacZ; ^cP < 0.01 vs Ad-LacZ.